Stonepine Capital Management LLC Purchases New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Stonepine Capital Management LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 182,317 shares of the company's stock, valued at approximately $618,000. Stonepine Capital Management LLC owned 0.12% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in XERS. JPMorgan Chase & Co. boosted its holdings in shares of Xeris Biopharma by 20.8% during the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company's stock worth $1,117,000 after purchasing an additional 67,557 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Xeris Biopharma by 57.3% during the fourth quarter. SG Americas Securities LLC now owns 94,671 shares of the company's stock worth $321,000 after purchasing an additional 34,469 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock worth $78,000 after purchasing an additional 5,500 shares during the period. Goldstein Advisors LLC boosted its holdings in shares of Xeris Biopharma by 24.2% during the fourth quarter. Goldstein Advisors LLC now owns 37,800 shares of the company's stock worth $128,000 after purchasing an additional 7,375 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth approximately $42,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.47% of the stock is owned by company insiders.

Xeris Biopharma Price Performance

Shares of XERS traded down $0.16 during mid-day trading on Wednesday, hitting $4.92. 2,361,690 shares of the company's stock were exchanged, compared to its average volume of 1,954,085. The company has a market cap of $769.41 million, a PE ratio of -10.93 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.86 and a 52 week high of $6.07. The company has a 50-day simple moving average of $4.74 and a 200 day simple moving average of $3.93.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. On average, analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on XERS shares. Leerink Partners lifted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler reissued a "neutral" rating and set a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Oppenheimer upped their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Xeris Biopharma currently has a consensus rating of "Moderate Buy" and an average target price of $6.25.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.